The three-year partnership integrates Cradle’s protein engineering AI into Bayer’s R&D workflows to improve lead optimization efficiency, developability, and scalability in biologics discovery.

Japan’s health regulator has approved finerenone for adults with chronic heart failure and left ventricular ejection fraction of at least 40%, expanding pharmacological options for a large, underserved patient population.

LynkuetTM (elinzanetant) receives first global approval in UK for moderate to severe menopause-related hot flashes, based on OASIS trials. It's the first dual neurokinin-targeted therapy.

BlueRock’s OpCT-001, the first iPSC-derived therapy for photoreceptor diseases, enters Phase 1/2a CLARICO trial to assess safety and impact on vision loss.

iCRO offers tailored services that support early research through Phase IV trials and Software as a Medical Device (SaMD) development for pharmaceutical, biotech, medical device, and digital health companies.

Bayer's Phase II panSOHO trial enrolls first patient to assess BAY 2927088 in HER2-mutant metastatic or unresectable tumors, including colorectal, uterine, bladder, and biliary cancers.

The company's pharma growth strategy advances with regulatory filings for key therapies, Phase III successes in oncology and radiology, and progress in gene therapy and precision oncology.

The REGENERATE-PD trial uses randomization and a double-blind design to evaluate AB-1005's efficacy and safety in treating moderate-stage Parkinson’s Disease, minimizing bias.

Bayer showcased tools for innovation in Radiology AI and digitalization and new collaborations in the area of AI at RSNA 2024.

Genvor will receive year-long access to lab space and equipment at Bayer’s LifeHub California @AgStart, one of the premier U.S. AgriFoodTech innovation ecosystems.